Cargando…
The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres
Selective internal radiation therapy has emerged as a well-accepted therapeutic for primary and metastatic hepatic malignancies. This therapeutic modality requires the combined efforts of multiple medical disciplines to ensure the safe delivery of yttrium-90 ((90)Y)-labeled microspheres. The develop...
Autores principales: | Westcott, Mark A., Coldwell, Douglas M., Liu, David M., Zikria, Joseph F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514171/ https://www.ncbi.nlm.nih.gov/pubmed/28740906 http://dx.doi.org/10.1016/j.adro.2016.08.003 |
Ejemplares similares
-
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016) -
Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres
por: Ebbers, S. C., et al.
Publicado: (2020) -
Yttrium-90 microsphere induced gastrointestinal tract ulceration
por: South, Christopher D, et al.
Publicado: (2008) -
Trans-arterial hepatic radioembolisation of yttrium-90 microspheres
por: Murthy, R, et al.
Publicado: (2006) -
Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017)